| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8771018 | The Journal of Urology | 2018 | 8 Pages |
Abstract
Men at favorable risk with Grade Group 2 disease who are considering active surveillance should be informed of the risks of harboring adverse pathological features which impact secondary therapies and an increased risk of cancer progression.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Derek J. Gearman, Alessandro Morlacco, John C. Cheville, Laureano J. Rangel, R. Jeffrey Karnes,